Miscellaneous Drugs

Colchicine

• The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of colchicine for the treatment of nonhospitalized patients with COVID-19, except in a clinical trial (BIIa).
• The Panel recommends against the use of colchicine for the treatment of hospitalized patients with COVID-19 (AI).

Fluvoxamine

• There is insufficient evidence for the Panel to recommend either for or against the use of fluvoxamine for the treatment of COVID-19.

Ivermectin

• The Panel recommends against the use of ivermectin for the treatment of COVID-19 (AIIa).

Intravenous Immunoglobulin

• The Panel recommends against the use of intravenous immunoglobulin (IVIG) for the treatment of acute COVID-19 in adults and children, except in a clinical trial (AIII). This recommendation should not preclude the use of IVIG when otherwise indicated for the treatment of complications that arise during the course of COVID-19.
• The Panel recommends using IVIG in combination with low to moderate dose glucocorticoids in hospitalized patients for the treatment of multisystem inflammatory syndrome in children (MIS-C) (AIIb).
• The Panel recommends against the routine use of IVIG monotherapy for the treatment of MIS-C unless glucocorticoid use is contraindicated (AIIb).

Metformin

• The Panel recommends against the use of metformin for the treatment of COVID-19 in nonhospitalized patients (BIIa) and hospitalized patients (BIII), except in a clinical trial.
• Patients with COVID-19 who are receiving metformin for an underlying condition should continue this therapy as directed by their health care provider (AIII).